Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32680984 | 0.76 | — | — | |
| SCHEMBL1484863 | 0.73 | HRH1 (0.35) | HRH1 | |
| SCHEMBL22012181 | 0.72 | SLC6A2 (0.30) | — | |
| SCHEMBL11894934 | 0.72 | — | — | |
| SCHEMBL21995644 | 0.71 | TLR8 (0.31) | — | |
| SCHEMBL21995645 | 0.71 | TLR8 (0.31) | — | |
| SCHEMBL104839 | 0.69 | HRH1 (0.35) | HRH1 | |
| SCHEMBL21407989 | 0.67 | — | — | |
| SCHEMBL21407988 | 0.67 | — | — | |
| SCHEMBL21407951 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-19 | — | — | US | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| CN-113166076-A | Heterocyclic compounds for the treatment of epilepsy | 大塚制药株式会社 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | SLC6A11, SCN1A, SCN1B | HRH1 558/4885 |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | HRH1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.